D. Logunov

发表

Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist

A. Gudkov, P. Stanhope-Baker, S. Makarov, 2013, Proceedings of the National Academy of Sciences.

Passive immunization with a recombinant adenovirus expressing an HA (H5)-specific single-domain antibody protects mice from lethal influenza infection.

T. I. Ivanova, S. Tillib, A. Gintsburg, 2013, Antiviral research.

Toll-like receptors and their adapter molecules

A. Gudkov, A. Gintsburg, D. Logunov, 2010, Biochemistry (Moscow).

Experimental approach to the gene therapy of motor neuron disease with the use of genes hypoxia-inducible factors

S. Illarioshkin, D. Logunov, E. Bocharov, 2014, Russian Journal of Genetics.

Mycoplasma infection with M. Arginini results in NF-κB constitutive activation and inhibition of apoptosis in cells expressing toll-like receptors TLR2/6

A. Gudkov, A. Gintsburg, D. Logunov, 2008, Molecular Genetics, Microbiology and Virology.

Development and characterization of two GP-specific monoclonal antibodies, which synergistically protect non-human primates against Ebola lethal infection.

A. Gintsburg, D. Logunov, B. Naroditsky, 2019, Antiviral research.

SARS-CoV-2-specific T cells and antibodies in COVID-19 protection: a prospective study

Elizaveta V. Romanova, G. Efimov, D. Logunov, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Adjuvantation of an Influenza Hemagglutinin Antigen with TLR4 and NOD2 Agonists Encapsulated in Poly(D,L-Lactide-Co-Glycolide) Nanoparticles Enhances Immunogenicity and Protection against Lethal Influenza Virus Infection in Mice

A. Gintsburg, D. Logunov, B. Naroditsky, 2020, Vaccines.

Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses

A. Gudkov, P. Stanhope-Baker, A. Gintsburg, 2016, PloS one.

Akhmatova Et Al. the Effect of a Bsa Conjugate of a Synthetic Hexasaccharide

D. Logunov, M. Gening, E. Kurbatova, 2022 .

Effective Genetic Expression of Nanoantibodies by Recombinant Adenoviral Vector in vitro

A. Gintsburg, D. Logunov, I. Tutykhina, 2011, Acta naturae.

Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance

E. D. Belyaeva, V. Gushchin, I. Grigoriev, 2022, Vaccines.

Stimulation of Dectin-1 and Dectin-2 during Parenteral Immunization, but Not Mincle, Induces Secretory IgA in Intestinal Mucosa

A. Gintsburg, D. Logunov, B. Naroditsky, 2018, Journal of immunology research.

[Sulfated polysaccharides of brown seaweeds--ligands of toll-like receptors].

V. I. Gorbach, D. Logunov, T. Zvyagintseva, 2012 .

Production of recombinant human lactoferrin in the allantoic fluid of embryonated chicken eggs and its characteristics.

A. Gintsburg, D. Logunov, B. Naroditsky, 2009, Protein expression and purification.

Обзор кандидатных вакцин для профилактики лихорадки Review of candidate vaccines for the prevention of Lassa fever

D. Logunov, B. Naroditsky, O. Popova, 2021 .

SARS-CoV-2-specific T cells and antibodies in COVID-19 protection: a prospective study.

Elizaveta V. Romanova, G. Efimov, D. Logunov, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Development and characterization of anti-SARS-CoV-2 intravenous immunoglobulin from COVID-19 convalescent plasma

E. Orlova, D. Logunov, M. Razumikhin, 2022, Immunotherapy.

Impact of pathogen reduction technologies on immunological propertiesof the COVID-19 convalescent plasma

A. Gintsburg, D. Logunov, S. Petrikov, 2020, medRxiv.

Antiviral Activity of N1,N3-Disubstituted Uracil Derivatives against SARS-CoV-2 Variants of Concern

V. Gushchin, A. Gintsburg, D. Logunov, 2022, International journal of molecular sciences.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Specific T Cells and Antibodies in Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study

Elizaveta V. Romanova, G. Efimov, D. Logunov, 2022, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

Impact of pathogen reduction methods on immunological properties of the COVID‐19 convalescent plasma

A. Gintsburg, D. Logunov, S. Petrikov, 2021, Vox sanguinis.

Combined Stimulation of Toll-Like Receptor 5 and NOD1 Strongly Potentiates Activity of NF-κB, Resulting in Enhanced Innate Immune Reactions and Resistance to Salmonella enterica Serovar Typhimurium Infection

A. Gudkov, A. Gintsburg, L. Burdelya, 2013, Infection and Immunity.

Autologous Genetically Enriched Leucoconcentrate in the Preventive and Acute Phases of Stroke Treatment in a Mini-Pig Model

D. Logunov, B. Naroditsky, Rustem Islamov, 2022, Pharmaceutics.

Production of the human β-interferon recombinant protein in avian cell culture

A. Gintsburg, D. Logunov, M. Shmarov, 2008, Molecular Genetics, Microbiology and Virology.

Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A

E. V. Usachev, V. Gushchin, A. Gintsburg, 2022, bioRxiv.

Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer

D. Logunov, E. Nelson, A. Ghochikyan, 2014, Journal of Translational Medicine.

NOD1/2 and the C-Type Lectin Receptors Dectin-1 and Mincle Synergistically Enhance Proinflammatory Reactions Both In Vitro and In Vivo

A. Gintsburg, D. Scheblyakov, D. Logunov, 2020, Journal of inflammation research.

Recombinant adenoviral nanostructures: Construction and prospects of use in medicine

A. Gintsburg, D. Logunov, B. Naroditsky, 2009 .

Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates

A. Gintsburg, D. Logunov, B. Naroditsky, 2022, Emerging microbes & infections.

Construction of recombinant adenoviral vector expressing genes of the conservative proteins M2 “ion channel” and nucleoprotein of influenza A virus

D. Logunov, E. Sedova, A. Lysenko, 2014, Molecular Genetics, Microbiology and Virology.

rAAV expressing recombinant neutralizing antibody for the botulinum neurotoxin type A prophylaxis

A. N. Noskov, A. Gintsburg, D. Logunov, 2022, Frontiers in Microbiology.

Human TRIM14 protects transgenic mice from influenza A viral infection without activation of other innate immunity pathways

D. Logunov, V. Nenasheva, V. Tarantul, 2021, Genes and immunity.

Variability of nonpathogenic influenza virus H5N3 under immune pressure.

O. Voronina, M. Kunda, N. Ryzhova, 2020, Acta virologica.

Chlamydial Type III Secretion System Needle Protein Induces Protective Immunity against Chlamydia muridarum Intravaginal Infection

A. Gintsburg, D. Logunov, B. Naroditsky, 2017, BioMed research international.

Cross-Reactive Fc-Fused Single-Domain Antibodies to Hemagglutinin Stem Region Protect Mice from Group 1 Influenza a Virus Infection

D. Logunov, O. Popova, M. Shmarov, 2022, Viruses.

Lipid-associated membrane lipopeptides of M. arginini activate NF-κB by interacting with TLR2/1, TLR2/6, and TLR2/CD14

A. Gudkov, A. Gintsburg, D. Scheblyakov, 2009, Molecular Genetics, Microbiology and Virology.

Dynamics of SARS-CoV-2 Major Genetic Lineages in Moscow in the Context of Vaccine Prophylaxis

E. D. Belyaeva, V. Gushchin, A. Gintsburg, 2022, International journal of molecular sciences.

Post-spinal cord injury astrocyte-mediated functional recovery in rats after intraspinal injection of the recombinant adenoviral vectors Ad5-VEGF and Ad5-ANG.

D. Logunov, B. Naroditsky, R. Islamov, 2017, Journal of neurosurgery. Spine.

Construction of CELO recombinant adenoviruses expressing avian type an influenza virus hemagglutinin gene and its use as vaccine against avian influenza virus type a H5N1 and H7N1

A. Gintsburg, D. Logunov, I. Chvala, 2011, Molecular Genetics, Microbiology and Virology.

Estimation of anti-orthopoxvirus immunity in Moscow residents and potential risks of spreading Monkeypox virus

E. D. Belyaeva, V. Gushchin, I. Grigoriev, 2022, Frontiers in Immunology.

Construction of a pIX-modified Adenovirus Vector Able to Effectively Bind to Nanoantibodies for Targeting

T. I. Ivanova, A. Gintsburg, D. Logunov, 2014, Acta naturae.

Predicting the dynamics of Covid-19 incidence and planning preventive vaccination measures for Moscow population based on mathematical modeling

D. Logunov, T. A. Semenenko, Мarina N. Asatryan, 2020, Journal of microbiology, epidemiology and immunobiology.

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

A. Gintsburg, D. Logunov, B. Naroditsky, 2020, The Lancet.

Stem cells of intestinal epithelium. The mechanisms of survival and the role of microbiota

D. Logunov, A. G. Konoplyannikov, D. Logunov, 2009 .

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

V. Gushchin, A. Gintsburg, D. Logunov, 2021, The Lancet.

Mycoplasma infection suppresses p53, activates NF-κB and cooperates with oncogenic Ras in rodent fibroblast transformation

A. Gudkov, L. Burdelya, D. Scheblyakov, 2008, Oncogene.

Safety and efficacy of the Russian COVID-19 vaccine: more information needed – Authors’ reply

D. Logunov, D. Shcheblyakov, I. Dolzhikova, 2020, The Lancet.

A Deep Look Into COVID-19 Severity Through Dynamic Changes in Blood Cytokine Levels

V. Gushchin, A. Gintsburg, D. Logunov, 2021, Frontiers in Immunology.

Induction of a Protective Heterosubtypic Immune Response Against the Influenza Virus by using Recombinant Adenoviral Vectors Expressing Hemagglutinin of the Influenza H5 Virus

A. Gintsburg, D. Logunov, B. Naroditsky, 2010, Acta naturae.

An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults

V. Gushchin, A. Gintsburg, D. Logunov, 2021, The Lancet Regional Health - Europe.

Vaccination potential of B and T epitope-enriched NP and M2 against Influenza A viruses from different clades and hosts

A. Gintsburg, D. Logunov, B. Naroditsky, 2018, PloS one.

Development of adenoviral vector-based mucosal vaccine against influenza

A. Gintsburg, D. Logunov, B. Naroditsky, 2011, Journal of Molecular Medicine.

Receptor Mincle promotes skin allergies and is capable of recognizing cholesterol sulfate

A. Tonevitsky, D. Sakharov, D. Maltseva, 2017, Proceedings of the National Academy of Sciences.

Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern

O. Voronina, M. Kunda, N. Ryzhova, 2021, bioRxiv.

Effects of gram-positive microorganisms and their products on in vivo survival of hemopoietic clonogenic cells

A. Gintsburg, D. Logunov, B. Naroditsky, 2008, Bulletin of Experimental Biology and Medicine.

Identification of HI-Like Loop in CELO Adenovirus Fiber for Incorporation of Receptor Binding Motifs

A. P. Karpov, Denis Y Logunov, Olga V Zubkova, 2007, Journal of Virology.

Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice

A. N. Noskov, D. Logunov, B. Naroditsky, 2019, Toxins.

Human TRIM14 protects transgenic mice from influenza A viral infection without activation of other innate immunity pathways

D. Logunov, V. Nenasheva, V. Tarantul, 2021, Genes & Immunity.

Interactions between Sulfated Polysaccharides from Sea Brown Algae and Toll-Like Receptors on HEK293 Eukaryotic Cells In Vitro

D. Logunov, T. Zvyagintseva, N. Besednova, 2012, Bulletin of Experimental Biology and Medicine.

The differences in immunoadjuvant mechanisms of TLR3 and TLR4 agonists on the level of antigen-presenting cells during immunization with recombinant adenovirus vector

D. Logunov, B. Naroditsky, R. Ataullakhanov, 2018, BMC Immunology.

Regulation of the Target Protein (Transgene) Expression in the Adenovirus Vector Using Agonists of Toll-Like Receptors

R. M. Khaitov, A. Gintsburg, D. Logunov, 2014, Acta naturae.

Recombinant avian adenovirus CELO expressing the human interleukin-2: characterization in vitro, in ovo and in vivo.

D. Logunov, B. Naroditsky, M. Shmarov, 2004, Virus Research.

Influence of integrin-binding motif (RGD) on the attachment and internalization of avian adenovirus CELO in mammalian cells

A. P. Karpov, D. Logunov, B. Naroditsky, 2008, Molecular Genetics, Microbiology and Virology.

Construction of the vector based on the CELO avian adenovirus genome providing enhanced expression of gene of secreted alkaline phosphatase in nonpermissive system in vitro and on vivo

D. Logunov, I. Tutykhina, M. Shmarov, 2008, Molecular Genetics, Microbiology and Virology.

Gene therapy of amyotrophic lateral sclerosis

N. Suponeva, S. Illarioshkin, D. Logunov, 2008, Bulletin of Experimental Biology and Medicine.

COVID-19 vaccination and HIV-1 acquisition

D. Livermore, H. Ertl, C. Czerkinsky, 2022, The Lancet.

Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants

A. Shchetinin, V. Gushchin, O. Voronina, 2021, Vaccines.

Association of Mycoplasma hominis infection with prostate cancer

E. Klein, A. Gudkov, A. Gintsburg, 2011, Oncotarget.

Non-thermal Plasma Causes p53-Dependent Apoptosis in Human Colon Carcinoma Cells

A. Grigoriev, A. Gintsburg, D. Scheblyakov, 2012, Acta naturae.

Revaccination in Age-Risk Groups with Sputnik V Is Immunologically Effective and Depends on the Initial Neutralizing SARS-CoV-2 IgG Antibodies Level

V. Gushchin, A. Gintsburg, D. Logunov, 2022, Vaccines.

Boosting of the SARS-CoV-2–Specific Immune Response after Vaccination with Single-Dose Sputnik Light Vaccine

G. Efimov, A. Gintsburg, D. Logunov, 2021, The Journal of Immunology.

Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals

V. Gushchin, A. Antinori, A. Gintsburg, 2022, medRxiv.

Sputnik Light and Sputnik V Vaccination Is Effective at Protecting Medical Personnel from COVID-19 during the Period of Delta Variant Dominance

V. Gushchin, A. Gintsburg, D. Logunov, 2022, Vaccines.

Protective Immune Response against Bacillus anthracis Induced by Intranasal Introduction of a Recombinant Adenovirus Expressing the Protective Antigen Fused to the Fc-fragment of IgG2a

A. N. Noskov, A. Gintsburg, D. Logunov, 2014, Acta naturae.

Nanobodies Are Potential Therapeutic Agents for the Ebola Virus Infection

O. Voronina, M. Kunda, N. Ryzhova, 2021, Acta naturae.

Spinal Cord Molecular and Cellular Changes Induced by Adenoviral Vector- and Cell-Mediated Triple Gene Therapy after Severe Contusion

Igor A. Lavrov, D. Logunov, B. Naroditsky, 2017, Front. Pharmacol..

rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19

A. Gintsburg, D. Logunov, B. Naroditsky, 2023, Frontiers in Immunology.

Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial – Authors' reply

D. Logunov, D. Shcheblyakov, I. Dolzhikova, 2021, The Lancet.

Topical bacterial lipopolysaccharide application affects inflammatory response and promotes wound healing.

A. Gintsburg, D. Scheblyakov, D. Logunov, 2013, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

SARS-CoV-2 evolution in a patient with secondary B-cell immunodeficiency: A clinical case

D. Chudakov, A. Shchetinin, V. Gushchin, 2022, Human vaccines & immunotherapeutics.

Analysis of the Efficiency of Gene-Cell Therapy in Transgenic Mice with Amyotrophic Lateral Sclerosis Phenotype

V. V. Solovieva, D. Logunov, B. Naroditsky, 2013, Bulletin of Experimental Biology and Medicine.

Adenoviral Transduction of Multipotent Mesenchymal Stromal Cells from Human Adipose Tissue with Bone Morphogenetic Protein BMP-2 Gene

D. Logunov, M. Shmarov, D. V. Gol’dshtein, 2013, Bulletin of Experimental Biology and Medicine.

Sputnik V protection from COVID-19 in people living with HIV under antiretroviral therapy

E. V. Tsyganova, V. Gushchin, A. Gintsburg, 2022, eClinicalMedicine.

Experimental approach to the gene therapy of motor neuron disease with the use of genes hypoxia-inducible factors

S. Illarioshkin, D. Logunov, E. Bocharov, 2014, Russian Journal of Genetics.

Myelin lipids in the development of the autoimmune response in multiple sclerosis

D. Logunov, A. Tukhvatulin, M. Zakharova, 2014, Neurochemical Journal.

New Therapy for Spinal Cord Injury: Autologous Genetically-Enriched Leucoconcentrate Integrated with Epidural Electrical Stimulation

Igor A. Lavrov, D. Logunov, B. Naroditsky, 2022, Cells.

Development and characterization of chimera of yellow fever virus vaccine strain and Tick-Borne encephalitis virus

A. Shchetinin, A. Gintsburg, D. Logunov, 2023, PloS one.

Formatted single-domain antibodies can protect mice against infection with influenza virus (H5N2).

T. I. Ivanova, S. Tillib, A. Gintsburg, 2013, Antiviral research.

Evaluation of Direct and Cell-Mediated Lactoferrin Gene Therapy for the Maxillofacial Area Abscesses in Rats

D. Logunov, B. Naroditsky, R. Islamov, 2021, Pharmaceutics.

A In Vitro and In Vivo Study of the Ability of NOD1 Ligands to Activate the Transcriptional Factor NF-kB

A. Gudkov, A. Gintsburg, L. Burdelya, 2011, Acta naturae.

Genetic features of highly pathogenic avian influenza viruses A(H5N8), isolated from the European part of the Russian Federation.

N. E. Sharapova, O. Voronina, M. Kunda, 2018, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Gene-modified leucoconcentrate for personalized ex vivo gene therapy in a mini pig model of moderate spinal cord injury

D. Logunov, A. Rizvanov, I. Salafutdinov, 2020, Neural regeneration research.

Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia

A. Gintsburg, D. Logunov, B. Naroditsky, 2017, Human vaccines & immunotherapeutics.

An Open, Non-Randomised, 1/2 Phase Study on the Safety, Tolerability, and Immunogenicity of Single Dose 'Sputnik Light' Vaccine for Prevention of Coronavirus Infection in Healthy Adults

V. Gushchin, A. Gintsburg, D. Logunov, 2021, SSRN Electronic Journal.

Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study

V. Gushchin, A. Gintsburg, D. Logunov, 2023, Frontiers in immunology.

Passive immunization with a recombinant adenovirus expressing an HA (H5)-specific single-domain antibody protects mice from lethal influenza infection.

T. I. Ivanova, S. Tillib, A. Gintsburg, 2013, Antiviral research.

[Ebola virus (Filoviridae: Ebolavirus: Zaire ebolavirus): fatal adaptation mutations].

A. Gintsburg, D. Logunov, D. N. Shcherbinin, 2021, Voprosy virusologii.